Target intelligence / Profile preview

Human papillomavirus type 16 L1 capsid protein (HPV-16 L1) (HPV-16 L1)

Target
HPV-16 L1
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Human papillomavirus type 16 L1 capsid protein is the primary structural component of the HPV-16 virion, which is the most prevalent high-risk HPV type associated with human malignancies [UniProt, 2024]. It self-assembles into 72 pentameric capsomeres to form an icosahedral capsid that protects the viral genome and facilitates binding to host cell heparan sulfate proteoglycans [PubMed, 2023]. As the most immunogenic protein of the virus, it is the central component of prophylactic vaccines such as Gardasil 9 and Cervarix, which utilize recombinant L1-based virus-like particles (VLPs) to elicit high titers of neutralizing antibodies [FDA, 2020]. These antibodies prevent the virus from infecting the basal epithelial cells, thereby blocking the development of HPV-associated cancers, including cervical, oropharyngeal, and anal cancers [StatPearls, 2023]. While highly effective as a preventive measure, L1-targeted interventions do not typically clear established infections or treat existing lesions, necessitating continued screening programs [NCI, 2022].

Other names
Major capsid protein L1HPV16 L1L1 proteinHPV-16 L1 VLP
02

Mechanism of action

Induction of neutralizing antibodies against the L1 protein to prevent viral attachment and entry into host epithelial cells [StatPearls, 2023].

03

Biological functions

Viral entryViral assemblyHost cell attachmentGenome packaging
04

Disease associations

Cervical cancerOropharyngeal cancerAnal cancerVulvar cancerVaginal cancerPenile cancerHuman papillomavirus infection
05

Safety considerations

Injection site reactionsSyncopeLack of therapeutic efficacy against existing infectionsPotential for genotype replacement
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

HPV-16 DNAL1 protein expressionAnti-HPV-16 L1 antibody titer

Beyond the preview

Go deeper on Human papillomavirus type 16 L1 capsid protein (HPV-16 L1) (HPV-16 L1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human papillomavirus type 16 L1 capsid protein (HPV-16 L1) (HPV-16 L1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call